15 completed, 4 terminated, 4 unknown, 1 active not recruiting. 24 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 15, Terminated 4, Unknown 4, Active not recruiting 1 |
| Phase 1 | 7 | Completed 4, Unknown 2, Terminated 1 |
Follow Hormone Refractory Prostate Cancer: new trials by email Literature Review of Hormone Refractory Prostate Cancer trials Research Report on Hormone Refractory Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment Carboplatin - Hormone Refractory Prostate Cancer | Phase 2 | Active not recruiting | Institute of Cancer Research, United Kingdom | 305 | 2017-05-25 | 2026-02-04 |
| A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients SHR3680 - Hormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 197 | 2016-04-12 | 2020-05-13 |
| Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer TKI258 - Hormone Refractory Prostate Cancer | Phase 2 | Completed | Korean Cancer Study Group | 44 | 2012-11-01 | 2021-02-18 |
| Study of Weekly Cabazitaxel for Advanced Prostate Cancer Cabazitaxel 10 mg/m2 - Hormone Refractory Prostate Cancer | Phase 2 | Completed | Spanish Oncology Genito-Urinary Group | 74 | 2012-05-01 | 2017-07-02 |
| Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer sipuleucel-T, abiraterone acetate - Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer | Phase 2 | Completed | Dendreon | 69 | 2011-12-01 | 2019-03-19 |
| Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel cediranib maleate, dasatinib - Hormone Refractory Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2010-10-01 | 2018-08-08 |
| Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer Bafetinib - Hormone Refractory Prostate Cancer | Phase 2 | Completed | CytRx | 23 | 2010-08-01 | 2011-12-15 |
| TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) Docetaxel, TroVax - Hormone Refractory Prostate Cancer | Phase 2 | Terminated | Oxford BioMedica | 25 | 2010-08-01 | 2020-10-19 |
| Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer IV fluorine-18 labeled methylcholine before PET/CT - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Completed | Queen's Medical Center | 25 | 2009-06-01 | 2017-08-14 |
| RNActive®-Derived Therapeutic Vaccine CV9103 - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Terminated | University of Florida | 6 | 2009-05-01 | 2012-04-04 |
| Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer Docetaxel * Sunitinib, Docetaxel - Hormone Refractory Prostate Cancer | Phase 2 | Unknown | Medical University of Vienna | 60 | 2008-11-01 | 2010-08-18 |
| Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer ADENOVIRUS/PSA VACCINE - Hormone Refractory Prostate Cancer | Phase 2 | Completed | David M Lubaroff | 32 | 2007-12-01 | 2023-04-28 |
| A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer Mycobacterium w., Docetaxel - Hormone Refractory Prostate Cancer | Phase 2 | Terminated | Cadila Pharnmaceuticals | 134 | 2007-11-01 | 2012-03-12 |
| A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel - Hormone Refractory Prostate Cancer | Phase 2 | Completed | Ascenta Therapeutics | 220 | 2007-10-01 | 2010-11-09 |
| Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients Fermented Wheat germ extract - Hormone Refractory Prostate Cancer | Phase 2 | Unknown | Sheba Medical Center | 60 | 2007-06-01 | 2009-07-31 |
| ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer ABI-008 - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Completed | Celgene | 102 | 2007-04-01 | 2019-11-22 |
| Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy Patupilone - Hormone Refractory Prostate Cancer | Phase 2 | Completed | British Columbia Cancer Agency | 73 | 2007-02-01 | 2010-11-05 |
| A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer Picoplatin, docetaxel - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Unknown | Poniard Pharmaceuticals | 95 | 2006-06-01 | 2009-01-21 |
| PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC Sargramostim, Docetaxel, Prednisone - Hormone Refractory Prostate Cancer | Phase 2 | Terminated | Veeda Oncology | 35 | 2006-04-01 | 2012-05-11 |
| A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer AT-101 - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Completed | Ascenta Therapeutics | 27 | 2005-12-01 | 2010-08-24 |
Showing 20 of 24. Sign in to see all of them.
Prostatic Neoplasms (9) · Neoplasm Metastasis (2) · Disease (1) · Neoplasms (1) · Prostatic Hyperplasia (1) · Salivary Gland Adenoma, Pleomorphic (1)
Genital Diseases (9) · Genital Diseases, Male (9) · Genital Neoplasms, Male (9) · Male Urogenital Diseases (9) · Neoplasms (9) · Neoplasms by Site (9) · Prostatic Diseases (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Docetaxel (6) · Prednisone (2) · gossypol acetic acid (2) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · Abiraterone Acetate (1) · Avemar (1) · Carboplatin (1) · Cisplatin (1) · Dasatinib (1) · Everolimus (1) · Mycobacterium w vaccine (1) · Strontium-89 (1) · Sunitinib (1) · TroVax (1) · amminedichloro(2-methylpyridine)platinum(II) (1)
Ascenta Therapeutics (2) · Alberta Health services (1) · Bayer (1) · British Columbia Cancer Agency (1) · Cadila Pharnmaceuticals (1) · Celgene (1) · CytRx (1) · Daniel George, MD (1) · David M Lubaroff (1) · Dendreon (1) · Institute of Cancer Research, United Kingdom (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Korean Cancer Study Group (1) · Medical University of Vienna (1) · National Cancer Institute (NCI) (1)
United States (13) · Canada (3) · Russia (2) · Austria (1) · China (1) · India (1) · Israel (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Lance Leopold, MD (2) · Amil Lal Bhat, MD (1) · Anna C. Ferrari, MD (1) · Arun Chawla, MD (1) · Arup Kumar Mandal, MD (1) · Bernie Eigl, MD (1) · Daniel J George, MD (1) · Daniel Levitt, M.D., Ph.D. (1) · David M Lubaroff, PhD (1) · Devakar Dalela, MD (1) · Dingwei Ye, M.D. (1) · Evan R Berger, MD (1) · Jackson Wu (1) · Jayesh Dhabalia, MD (1)
PMID 11839651, PMID 21150709, PMID 21982118, PMID 22341993, PMID 23877659, PMID 24788563, PMID 26912444, PMID 34286638, PMID 35241087, PMID 37058234
2004 (1), N01CM00071 (1), R21CA139687 (1), U01CA070095 (1), U01CA132123 (1)